Takeda Pharmaceutical (TAK) Receivables - Net (2017 - 2026)

Takeda Pharmaceutical's Receivables - Net history runs 10 years deep, the most recent figure standing at $6.2 billion for Q1 2026.

• On a quarterly basis, Receivables - Net rose 23.34% year-over-year to $6.2 billion in Q1 2026; TTM through Mar 2026 was $6.2 billion, a 23.34% increase from a year earlier, with the FY2026 full-year figure at $6.5 billion, up 28.29% from the prior year.
• Receivables - Net advanced to $6.2 billion in Q1 2026 per TAK's latest filing, from $4.8 billion in the prior quarter.
• Across five years, Receivables - Net topped out at $6.2 billion in Q1 2026 and bottomed at -$51.4 million in Q1 2022.
• The 5-year median for Receivables - Net is $4.8 billion (2023), against an average of $4.2 billion.
• Across the five-year window, Receivables - Net sank 100.69% in 2022 and soared 16583.02% in 2025, its largest moves.
• Year by year, Receivables - Net stood at $5.0 billion in 2022, then declined by 3.22% to $4.8 billion in 2023, then dropped by 3.42% to $4.7 billion in 2024, then grew by 2.26% to $4.8 billion in 2025, then soared by 30.23% to $6.2 billion in 2026.
• Per Business Quant, the three latest TAK Receivables - Net figures stand at $6.2 billion (Q1 2026), $4.8 billion (Q4 2025), and $4.7 billion (Q3 2025).